ADMA Biologics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
ADMA Biologics Inc Announces Closing Of Initial Public Offering
ADMA Biologics, Inc announced that the closing of its previously announced initial public offering of 3,352,941 shares of its common stock at a public offering price of $8.50 per share. Aggregate net proceeds to ADMA, after deducting underwriting discounts and commissions will be approximately $26.5 million. Oppenheimer & Co. acted as sole book-running manager for the offering. Ladenburg Thalmann & Co. Inc., Maxim Group LLC and Laidlaw & Company (UK) Ltd. acted as co-managers.
Latest Developments for ADMA Biologics Inc
Latest Key Developments in Biotechnology
- Omeros Corp prices $35.0 million public offering of common stock
- Navidea Biopharmaceuticals Inc announces presentation of Lymphoseek three-year recurrence and survival outcomes after Sentinel Lymph Node Biopsy in Patients with Breast Cancer and Melanoma
- Algeta appoints Thomas Ramdahl as new Managing Director
- Algeta ASA appoints chairman; to apply for delisting of shares from Oslo Stock Exchange
- Share this
- Digg this